✦ LIBER ✦

Second- and Third-line Treatment of Patients With Non–Small-Cell Lung Cancer With Erlotinib in the Community Setting: Retrospective Study of Patient Healthcare Utilization and Symptom Burden

✍ Scribed by Edward J. Stepanski; Arthur C. Houts; Lee S. Schwartzberg; Mark S. Walker; Carolina M. Reyes; Johnetta Blakely

Book ID: 115076752
Publisher: CIG Media Group, LP.
Year: 2009
Tongue: English
Weight: 260 KB
Volume: 10
Category: Article
ISSN: 1525-7304
DOI: 10.3816/clc.2009.n.080

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical surrogate markers of survival i

Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second–third line erlotinib

✍ Cedrés, Susana; Prat, Aleix; Martínez, Pablo; Pallisa, Esther; Sala, Gemma; Andr 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 341 KB

Clinical retrospective analysis of erlot

Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer

✍ Marco Platania; Francesco Agustoni; Barbara Formisano; Milena Vitali; Monika Duc 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 101 KB

Activity and safety of erlotinib as seco

Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial

✍ David Rossi; Donatella Dennetta; Marcello Ugolini; Vincenzo Catalano; Paolo Ales 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 129 KB

Randomized Phase III Trial of Erlotinib

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

✍ Kawaguchi, T.; Ando, M.; Asami, K.; Okano, Y.; Fukuda, M.; Nakagawa, H.; Ibata, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 183 KB

Second-line treatment with vinorelbine a

Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study

✍ Agelaki, Sophia; Bania, Helen; Kouroussis, Charalambos; Blazoyiannakis, George; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Comparison of adverse events and efficac

Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis

✍ Tsukasa Yoshida, Kazuhiko Yamada, Koichi Azuma, Akihiko Kawahara, Hideyuki Abe, 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 225 KB